News

NVMS award for Albert Heck

The Dutch Society for Mass Spectrometry (NVMS) has honoured Albert Heck with the Outstanding Research Award 2016. Heck received the award for his many excellent contributions to the field of Mass Spectrometry. Heck is Professor of Biomolecular Mass Spectrometry and Proteomics at Utrecht University, and Scientific Director of the Netherlands Proteomics Centre and the large-scale research facility Proteins At Work.

Collaboration Neon Therapeutics and NKI

The Netherlands Cancer Institute (NKI) together with the Amsterdam Biotherapeutics Unit has entered into a collaborative reseach agreement with Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer.

2nd Chemical Immunology Conference - registration is now open!

On April 1, 2016, the second Chemical Immunology Conference of the Institute for Chemical Immunology will take place in the Rode Hoed in Amsterdam.

Heck group in European programme to make large-scale protein analysis clinically applicable

Within five years, the first hospitals should be able to completely analyse all of the proteins in a patient’s blood and urine in order to provide more individualised treatment. That is the ambition of the researchers at Utrecht University and their four European partners. The researchers have received a 3.7 million Euro grant for their MSmed research proposal as part of the Future and Emerging Technologies programme within the Horizon 2020 project. On 14 and 15 January, MSmed officially kicked off its activities at an event in Copenhagen.

Novel EU 2020 grant for Carl Figdor

ICI researcher Carl Figdor (Radboud UMC, Dept. of Tumor Immunology, theme Cancer development en immune defence) received a novel EU 2020 grant named PRECIOUS to develop biodegradable nanomedicines for multimodal precision cancer immunotherapy. In this five year program (8.3 Million Euro’s) the team will produce nanoparticles filled with compounds that manipulate the immune system and test these in the clinic.

New imaging technology sheds light on pathogens during degradation

In a paper in Chemical Science, ICI PhD student Daphne van Elsland (Leiden University) and colleagues have combined two techniques that together enable visualization of bacteria being degraded by immune cells. 

Ton Schumacher receives Meyenburg Award 2015

Ton Schumacher (Netherlands Cancer Institute and ICI executive board member) has received the Meyenburg Award 2015 on Wednesday, September 11th.

The award is established by the German Meyenburg Foundation, which aims to stimulate excellence in cancer research. The prize is awarded annually to an internationally acclaimed scientist for his or her outstanding achievements. Schumacher receives this award in recognition of his research on T cell recognition of human cancer.

Sjaak Neefjes appointed as Van Loghem Laureate 2015

NKI researcher and ICI scientific director Sjaak Neefjes will give the Van Loghem Lecture 2015 at the annual meeting of the Dutch Society for Immunology on Wednesday December 16th, 2015. With this, Neefjes joins the rank of renowned Dutch immunologists who previously received this honor.

Prestigious American Chemical Society award for Albert Heck

The American Chemical Society has honoured Albert Heck with the ‘ACS Frank H. Field and Joe L. Franklin Award for Outstanding Achievements in Mass Spectrometry’. Heck receives the award for his development of new methods and techniques to identify and study the structure and function of proteins and protein complexes. 

In the field of Chemistry, the American Chemical Society Awards are considered to be very prestigious, and are almost exclusively presented to researchers from America. The Award will be presented during the meetings of the American Chemical Society in March 2016.

NKI researchers discover new anti-cancer drug resistance mechanisms

ICI researchers at the Netherlands Cancer Institute have discovered three new resistance mechanisms of cancer cells against the commonly used anti-cancer drugs doxorubicin and etoposide. In The Netherlands alone, thousands of patients a year are treated with one of these drugs. But they don't always work well for every patient. The new discovery might help predict whether a patient will or will not benefit from them.

Pages